Pronova BioPharma ASA har sikret seg et nytt patent i USA.
Pronova BioPharma ASA som produserer marinbaserte omega-3 avledede legemidler, har fått et nytt patent i USA for legemiddelet Omacor®/Lovaza(TM). Det fremgår av en børsmelding fra selskapet mandag 5. juli.
Patentet ble oppført i «Orange Book» den 2. juli 2010, fremgår det av meldingen.
Selskapet har utviklet en teknologi for reduksjon av miljøgifter i oljer, og kan med det tilby legemidler med svært lave konsentrasjoner av miljøgifter.
Les børsmeldingen her:
Adds another patent to the Orange Book listing of Omacor®/Lovaza(TM)
Pronova BioPharma ASA's newly issued U.S. Patent No. 7,732,488 was listed on 2 July in the Orange Book. This is the 4th patent, emanating from Pronova BioPharma's pioneering research on essential fatty acids, to be listed by the U.S. Food and Drug Administration - an achievement which further solidifies Pronova BioPharma's position as the first and only company with an EU and FDA approved Omega-3 derived prescription drug.
The new patent is entitled «Pharmaceutical composition comprising low concentration of environmental pollutants.» The listing of Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange
Book, identifies drug products approved on the basis of safety and effectiveness, and may be viewed on FDA's website:
Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)
– I am proud that Pronova BioPharma through our process development efforts has been able to develop a technology which removes environmental pollutants and thereby sets a new industry standard towards reductions of environmental pollutants in Omega-3s. Pronova BioPharma's technology and the newly listed composition patent ensure that our blockbuster drug Omacor®/Lovaza(TM) is available for million of patients with very low concentrations of pollutants, says CEO and President of Pronova BioPharma, Morten Jurs.
Pronova BioPharma's patents, currently listed in the Orange Book, directed to Omacor®/Lovaza(TM) include: U.S. Patent Nos. 5,656,667, 5,502,077, and the newly listed 7,732,448.
Additionally, the U.S. Patent and Trademark Office recently granted two process patents related to removing environmental pollutants and cholesterol (i.e., U.S. Patent Nos. 7,678,940 and 7,718,698). Pronova BioPharma's unique and complex stripping technology reduces environmental pollutants and cholesterol from oils irrespective of the quality of oil. Omacor®/Lovaza(TM) is one of the safest pharmaceutical drugs in the cardiovascular segment.
